A new report, commissioned by LogiPharma, has revealed the increasing impact of artificial intelligence and machine learning on pharmaceutical supply chains, emphasising how AI has evolved from an accessory to a strategic necessity for the entire industry. The LogiPharma AI Report 2024, based on a survey conducted among one hundred supply chain professionals in the life sciences sector across Europe, demonstrates that AI is rapidly becoming central to improving efficiency, resilience, and operational excellence in pharmaceutical supply chains.
According to the report, over half of respondents expect a return on investment from AI and ML initiatives within two to three years, underlining the sector's confidence in the potential of this technology. "Our delegates and partners consistently tell us that AI is transforming the way they tackle supply chain challenges," said Will Robinson, Director of the LogiPharma conference. "AI is no longer just a tool to boost efficiency; it is becoming a key enabler for pharmaceutical companies seeking to meet the demands of a complex and rapidly evolving market."
The report highlights several key areas where AI is already making a difference. It is playing a crucial role in optimising inventory management, with 40% of companies prioritising AI for demand forecasting and waste minimisation, particularly for temperature-sensitive products such as biologics and vaccines. Additionally, 69% of pharmaceutical companies have already implemented AI-driven automated alert systems to monitor cold chain logistics in real time, ensuring the safe and effective transport of temperature-sensitive goods.
Despite the promise AI offers in addressing challenges like inventory optimisation and supply chain visibility, the journey is not without obstacles. Data integration remains a significant challenge, as many companies strive for real-time visibility across fragmented systems and partner networks. Currently, only between 11% and 25% of supply chain partners use AI-enabled processes, indicating that while the benefits of an interconnected, AI-enabled ecosystem are evident, broader adoption is required for a full impact.
"Without data, there is no AI. This is particularly relevant for supply chains, which operate in a state of constant change and are always reliant on partners for shared business process execution," explained Shabbir Dahod, President and CEO of TraceLink. "Considering that a supply chain is only as strong as its weakest link, the main challenge for executives looking to implement an AI-based supply chain strategy is clear: end-to-end digital partner networks must be established to obtain the real-time data needed for orchestrating supply chain processes."
The report also underscores the importance of AI in digital transformation, with 44% of respondents focusing on AI-based sales and operations planning to enhance agility in response to market fluctuations and regulatory changes. Stefano Chiei, EMEA/EE Operations Director at Advanced Bionics, Sonova Holding, commented: "AI is not reinventing the wheel, but it is providing new solutions for efficiency and helping the industry unlock new opportunities."
